Biofrontera vs IM Cannabis
Biofrontera and IM Cannabis are similar in size: $41.7m and $39.2m of revenue in their latest fiscal years. Biofrontera grew faster (11.7% against -0.7%). IM Cannabis kept more of each dollar of sales as profit: a net margin of -20.7% against -25.3%.
| Latest fiscal year | BiofronteraBFRI, 2025 | IM CannabisIMCC, 2025 |
|---|---|---|
| Revenue | $41.7m | $39.2m |
| Revenue growth | 11.7% | -0.7% |
| Net income | −$10.5m | −$8.1m |
| Operating margin | — | -21.2% |
| Net margin | -25.3% | -20.7% |
| Return on equity | -141.3% | — |
| Free cash flow | −$13.4m | $3.4m |
| Cash | $6.4m | $2.0m |
| Total debt | $0 | $11.8m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 92 | — |
| Market value | $12.5m | $4.2m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |